5 unchanged sentences
Based upon that evaluation, our principal executive officer who is also acting as our principal financial officer concluded that, as of the end of the period covered in this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer who is also acting as our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
−Removed: Our principal executive officer who is also acting as our principal financial officer do not expect that our disclosure controls or internal controls will prevent all error and all fraud.
+Added: Our principal executive officer who is also acting as our principal financial officer does not expect that our disclosure controls or internal controls will prevent all error and all fraud.
Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives, a control system, no matter how well conceived and operated, can provide only reasonable, but not absolute assurance that the objectives of the system are met.
6 unchanged sentences
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f).
−Removed: Under the supervision and with the participation of our Chief Executive Officer and Vice President, Finance and Corporate Controller, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
+Added: Under the supervision and with the participation of our Chief Executive Officer and Vice President, Finance and Chief Accounting Officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.
Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2020.
+Added: Table of Con tents
Attestation Report of the Independent Registered Public Accounting Firm
4 unchanged sentences
OTHER INFORMATION
+Added: Table of Con tents
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by item 10 is incorporated herein by reference from the Company’s Proxy Statement, which will be filed with the SEC within 120 days after the end of the Company’s 2020 fiscal year pursuant to Regulation 14A for its 2021 Annual Meeting of Stockholders.
−Removed: EXCUTIVE COMPENSATION
+Added: EXECUTIVE COMPENSATION
The information required by item 11 is incorporated herein by reference from the Company’s Proxy Statement, which will be filed with the SEC within 120 days after the end of the Company’s 2020 fiscal year pursuant to Regulation 14A for its 2021 Annual Meeting of Stockholders.
5 unchanged sentences
The information required by item 14 is incorporated herein by reference from the Company’s Proxy Statement, which will be filed with the SEC within 120 days after the end of the Company’s 2020 fiscal year pursuant to Regulation 14A for its 2021 Annual Meeting of Stockholders.
+Added: Table of Con tents
+Added: Number Description Form Exhibit Filing Date
2.1^ Agreement and Plan of Merger, dated as of August 7, 2017, by and among the Registrant, Galena Bermuda Merger Sub, Ltd., Sellas Intermediate Holdings I, Inc., Sellas Intermediate Holdings II, Inc.
and SELLAS Life Sciences Group Ltd, as amended (included as Annex A to the proxy statement/prospectus/consent solicitation statement)
−Removed: August 8, 2017
+Added: 8-K 2.1 August 8, 2017
3.1 Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.), amended as of December 27, 2017
−Removed: April 13, 2018
+Added: 10-K 3.1 April 13, 2018
3.2 Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock
−Removed: March 12, 2018
+Added: 8-K 3.1 March 12, 2018
3.3 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant
−Removed: November 6, 2019
+Added: 8-K 3.1 November 6, 2019
3.4 Amended and Restated By-Laws of the Registrant
−Removed: January 5, 2018
+Added: 8-K 3.3 January 5, 2018
4.1* Form of Common Stock Certificate
−Removed: April 13, 2018
+Added: 10-K 4.1 April 13, 2018
4.2 Form of Contingent Value Rights Agreement among the Registrant (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc., and Robert E Kennedy, dated April 13, 2011
−Removed: April 14, 2011
+Added: 8-K 10.1 April 14, 2011
4.3 First Amendment to Contingent Value Rights Agreement among the Registrant (formerly RXi Pharmaceuticals Corporation), Computershare Trust Company, N.A., Computershare Inc., and Robert E Kennedy, dated February 15, 2012
−Removed: March 28, 2012
−Removed: Registration Rights Agreement dated May 10, 2016 between the Registrant and Purchasers
−Removed: Series A Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd.
−Removed: dated May 10, 2016
−Removed: Series B Common Stock Purchase Warrant assigned to JGB (Cayman) Newton Ltd.
−Removed: dated May 10, 2016
−Removed: Subsidiary Guarantee dated May 10, 2016 between the Registrant and JGB Collateral LLC
−Removed: Security Agreement dated May 10, 2016 between the Registrant and JGB Collateral LLC
−Removed: Amended and Restated 9% Original Issue Discount Senior Secured Debenture Due November 10, 2018, issued to JGB (Cayman) Newton Ltd.
−Removed: as of August 22, 2016
−Removed: August 23, 2016
−Removed: Amendment Agreement, dated as of July 10, 2017, by and between JGB Cayman (Newton) Ltd.
−Removed: and the Registrant with respect to the 9% Original Issue Discount Senior Secured Convertible Debenture in the Original Issue Amount of $25,350,000 Issued and Sold to JGB Cayman (Newton) Ltd.
−Removed: by the Registrant
−Removed: July 11, 2017
−Removed: Consent, dated as of August 7, 2017, made by JGB (Cayman) Newton Ltd., in favor of the Registrant
−Removed: August 8, 2017
−Removed: Form of warrants granted on May 8, 2013 under the Loan and Security Agreement
+Added: 10-K 10.2 March 28, 2012
4.4 Form of Warrant Agreement by and among the Registrant, Computershare Inc.
and Computershare Trust Company, N.A.
−Removed: September 18, 2013
+Added: 8-K 4.1 September 18, 2013
4.5 Warrant Agreement, dated as of March 18, 2015, by and among the Registrant, Computershare, Inc.
and Computershare Trust Company, N.A.
−Removed: August 6, 2015
+Added: 10-Q 4.1 August 6, 2015
4.6 Form of Warrant Agreement by and among the Registrant, Computershare Inc.
and Computershare Trust Company, N.A.
−Removed: January 7, 2016
+Added: 8-K 4.1 January 7, 2016
4.7 Form of Warrant, issued by the Registrant to the Investors on July 13, 2016
+Added: 8-K 4.1 July 8, 2016
4.8 Form of Warrant Agreement, including the Form of Warrant, issued by the Registrant to the Investors on February 13, 2017
−Removed: February 10, 2017
+Added: 8-K 4.1 February 10, 2017
4.9 Warrant issued to EQC Private Markets SAC Fund Ltd – EQC Biotech Sely I Fund
−Removed: January 5, 2018
−Removed: Warrant Exchange Agreement by and between the Registrant and CVI Investments, Inc., dated February 6, 2018
−Removed: April 13, 2018
−Removed: Promissory Note by and between the Registrant and CVI Investments, Inc., dated February 6, 2018
−Removed: April 13, 2018
−Removed: Warrant Exchange Agreement by and between the Registrant and Anson Investments Master Fund LP, dated February 7, 2018
−Removed: April 13, 2018
−Removed: Warrant Exchange Agreement by and between the Registrant, Sabby Healthcare Master Fund Ltd and Sabby Volatility Warrant Master Fund Ltd, dated February 8, 2018
−Removed: April 13, 2018
−Removed: Warrant Exchange Agreement by and between the Registrant and Hudson Bay Master Fund Agreement, dated February 9, 2018
−Removed: April 13, 2018
−Removed: Promissory Note by and between the Registrant and Hudson Bay Master Fund Agreement, dated February 9, 2018
−Removed: April 13, 2018
−Removed: Warrant Exchange Agreement by and between the Registrant and Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, dated February 13, 2018
−Removed: April 13, 2018
−Removed: Promissory Note by and between the Registrant and Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, dated February 13, 2018
−Removed: April 13, 2018
−Removed: Warrant Exchange Agreement by and between the Registrant and Lincoln Park Capital LLC, dated February 14, 2018
−Removed: April 13, 2018
−Removed: Warrant Exchange Agreement by and between the Registrant and Empery Asset Master, Ltd., dated February 21, 2018
−Removed: April 13, 2018
−Removed: Warrant Exchange Agreement by and between the Registrant and Empery Tax Efficient, LP, dated February 21, 2018
−Removed: April 13, 2018
−Removed: Warrant Exchange Agreement by and between the Registrant and Empery Tax Efficient II, LP, dated February 21, 2018
−Removed: April 13, 2018
−Removed: Promissory Note by and between the Registrant and Empery Asset Master, Ltd., dated February 21, 2018
−Removed: April 13, 2018
−Removed: Promissory Note by and between the Registrant and Empery Tax Efficient, LP, dated February 21, 2018
−Removed: April 13, 2018
−Removed: Promissory Note by and between the Registrant and Empery Tax Efficient II, LP, dated February 21, 2018
−Removed: April 13, 2018
+Added: 8-K 10.5 January 5, 2018
4.10 Warrant Agreement including form of accompanying Common Warrant as Exhibit B thereto, dated as of July 16, 2018, among the Registrant, Computershare, Inc., and Computershare Trust Company N.A.
−Removed: July 18, 2018
+Added: 8-K 10.1 July 18, 2018
4.11 Amendment to Warrant Agreement including form of accompanying Common Warrant as Exhibit B thereto, dated as of July 16, 2018, among the Registrant, Computershare, Inc., and Computershare Trust Company N.A.
+Added: 8-K 10.2 July 9, 2019
4.12 Form of Pre-funded Warrant in connection with July 2018 public offering
−Removed: July 18, 2018
+Added: 8-K 10.2 July 18, 2018
4.13 Form of Warrant issued in exchange of Series A Preferred Stock in connection with July 2018 public offering
−Removed: July 18, 2018
+Added: 8-K 10.3 July 18, 2018
+Added: Table of Con tents
+Added: Number Description Form Exhibit Filing Date
4.14 Warrant Exchange Agreement by and between the Registrant and Intracoastal Capital LLC dated May 25, 2018 (including as Exhibit A thereto, that certain Convertible Promissory Note by and between the Registrant and Intracoastal Capital LLC dated May 25, 2018)
+Added: 8-K 10.1 June 1, 2018
4.15 Form of New Warrant issued in connection with Warrant Exercise Agreement dated March 6, 2019
−Removed: March 6, 2019
+Added: 8-K 4.1 March 6, 2019
4.16 Warrant Agreement, including form of accompanying Common Warrant as Exhibit B thereto, dated as of June 18, 2019, among the Registrant, Computershare Inc., and Computershare Trust Company N.A.
−Removed: June 18, 2019
+Added: 8-K 10.1 June 18, 2019
4.17 Form of Pre-Funded Warrant in connection with June 2019 public offering
−Removed: June 18, 2019
+Added: 8-K 10.2 June 18, 2019
+Added: 4.18 Form of Warrant in connection with January Registered Direct 2020
+Added: 8-K 4.1 January 10, 2020
+Added: 4.19 Form of Pre-Funded Warrant in connection with January registered Direct 2020 Offering
+Added: 8-K 4.2 January 10, 2020
+Added: 4.20 Form of Warrant in connection with July 2020 Private Placement
+Added: 8-K 4.1 August 4, 2020
4.21 Description of Securities
+Added: 10-K 4.41 March 13, 2020
9.1 Securities Purchase Agreement dated March 7, 2018 by and between the Registrant and certain investors
−Removed: March 12, 2018
+Added: 8-K 10.1 March 12, 2018
10.1* The Registrant’s 2016 Incentive Plan effective as of July 14, 2016
−Removed: August 22, 2016
+Added: 8-K 10.3 August 22, 2016
10.2* Form Incentive Stock Option granted under the Registrant’s 2016 Incentive Plan
−Removed: August 8, 2015
+Added: 10-Q 10.1 August 8, 2015
10.3* Form Nonstatutory Stock Option granted under the Registrant’s 2016 Incentive Plan
−Removed: August 8, 2015
+Added: 10-Q 10.2 August 8, 2015
10.4* SELLAS Life Sciences Group, Ltd Stock Incentive Plan #1
−Removed: October 30, 2017
+Added: S-4/A 10.61 October 30, 2017
10.5* Form of Restricted Stock Unit Grant and Agreement under SELLAS Life Sciences Group Ltd Stock Incentive Plan #1
−Removed: October 30, 2017
+Added: S-4/A 10.63 October 30, 2017
10.6* 2017 Equity Incentive Plan of the Registrant
−Removed: January 5, 2018
+Added: 8-K 10.10 January 5, 2018
10.7* 2017 Employee Stock Purchase Plan of the Registrant
−Removed: January 5, 2018
+Added: 8-K 10.11 January 5, 2018
10.8* Form of Stock Option Grant Notice and Option Agreement under the 2017 Equity Incentive Plan.
−Removed: March 19, 2018
+Added: 8-K 10.2 March 19, 2018
10.9* Form of Restricted Stock Unit Grant and Agreement under the 2017 Equity Incentive Plan.
−Removed: April 13, 2018
+Added: 10-K 10.9 April 13, 2018
10.10* Employment Agreement by and between SELLAS Life Sciences Group AG and Angelos Stergiou, effective September 1, 2016
−Removed: October 30, 2017
+Added: S-4/A 10.53 October 30, 2017
10.11* Employment Agreement by and between SELLAS Life Sciences Group AG and Gregory Torre, effective September 1, 2016
−Removed: October 30, 2017
+Added: S-4/A 10.54 October 30, 2017
10.12* Employment Agreement by and between SELLAS Life Sciences Group AG and Nicholas Sarlis, effective September 19, 2016
−Removed: October 30, 2017
+Added: S-4/A 10.55 October 30, 2017
10.13* Employment Agreement by and between SELLAS Life Sciences Group Ltd and Aleksey Krylov, dated October 24, 2017
−Removed: October 30, 2017
+Added: S-4/A 10.56 October 30, 2017
10.14* Retention Agreement Letter by and between SELLAS Life Sciences Group Ltd and Gregory Torre, dated July 31, 2017
−Removed: October 30, 2017
+Added: S-4/A 10.57 October 30, 2017
10.15* Retention Agreement Letter by and between SELLAS Life Sciences Group Ltd and Nicholas Sarlis, dated August 2, 2017
−Removed: October 30, 2017
+Added: S-4/A 10.58 October 30, 2017
10.16* Letter Employment Agreement by and between SELLAS Life Sciences Group, Inc.
and Barbara Wood, dated March 14, 2018
−Removed: March 19, 2018
+Added: 8-K 10.1 March 19, 2018
+Added: Table of Con tents
+Added: Number Description Form Exhibit Filing Date
10.17+ Patent and Technology License Agreement, dated September 11, 2006, by and among the Board of Regents of the University of Texas System, the University of Texas M.D.
2 unchanged sentences
(formerly Advanced Peptide Therapeutics, Inc.)
−Removed: August 15, 2011
+Added: 10-Q 10.1 August 15, 2011
10.18 Amendment No.
3 unchanged sentences
(formerly Advanced Peptide Therapeutics, Inc.)
−Removed: August 15, 2011
+Added: 10-Q 10.2 August 15, 2011
10.19 Amendment No.
3 unchanged sentences
(formerly Advanced Peptide Therapeutics, Inc.)
−Removed: August 15, 2011
+Added: 10-Q 10.3 August 15, 2011
10.20 Amendment No.
3 unchanged sentences
(formerly Advanced Peptide Therapeutics, Inc.)
−Removed: August 15, 2011
+Added: 10-Q 10.4 August 15, 2011
10.21+ Amendment No.
3 unchanged sentences
(formerly Advanced Peptide Therapeutics, Inc.)
−Removed: August 15, 2011
+Added: 10-Q 10.5 August 15, 2011
10.22+ Amendment No.
3 unchanged sentences
(formerly Advanced Peptide Therapeutics, Inc.)
−Removed: August 15, 2011
+Added: 10-Q 10.6 August 15, 2011
10.23 Scientific Advisory Agreement between the Registrant (formerly Galena Biopharma, Inc.) and George E.
Peoples, Ph.D., dated April 13, 2011
−Removed: August 15, 2011
+Added: 10-Q 10.10 August 15, 2011
10.24+ Exclusive License Agreement, dated as of July 11, 2011, by and among The Henry M.
Jackson Foundation for the Advancement of Military Medicine, Inc., the Registrant (formerly Galena Biopharma, Inc.) and its wholly owned subsidiary, Apthera, Inc.
−Removed: August 15, 2011
+Added: 10-Q 10.12 August 15, 2011
10.25+ Exclusive License Agreement, dated as of September 16, 2011, by and among The Henry M.
1 unchanged sentence
Anderson Cancer Center and the Registrant (formerly Galena Biopharma, Inc.)
−Removed: September 21, 2011
+Added: 8-K 10.1 September 21, 2011
10.26+ License Agreement, effective as of April 30, 2009, between Kwangdong Pharmaceutical Co., Ltd.
and Apthera, Inc.
−Removed: March 28, 2012
+Added: 10-K 10.45 March 28, 2012
10.27 Amendment No.
1 to License Agreement, dated as of January 13, 2012, by and among Apthera, Inc., Kwangdong Pharmaceutical Co., Ltd., and the Registrant
−Removed: March 28, 2012
+Added: 10-K 10.46 March 28, 2012
10.28+ License and Supply Agreement, effective December 3, 2012, by and between the Registrant and ABIC Marketing Limited, a subsidiary of Teva Pharmaceuticals
−Removed: March 12, 2013
+Added: 10-K 10.43 March 12, 2013
+Added: Table of Con tents
+Added: Number Description Form Exhibit Filing Date
10.29+ License and Development Agreement, dated January 13, 2014, between the Registrant and Dr.
Reddy’s Laboratories, Ltd.
−Removed: March 17, 2014
+Added: 10-K 10.36 March 17, 2014
10.30+ Exclusive License Agreement, dated as of December 20, 2013, between Mills Pharmaceuticals, LLC and BioVascular, Inc.
−Removed: March 17, 2014
+Added: 10-K 10.37 March 17, 2014
10.31 Amendment of the Exclusive License Agreement by and between Mills Pharmaceuticals, LLC and BioVascular, Inc.
−Removed: September 11, 2017
−Removed: License Agreement by and between SELLAS Life Sciences, Inc.
−Removed: and Madison Avenue Suites LLC, dated March 20, 2017
−Removed: October 30, 2017
+Added: 8-K 10.1 September 11, 2017
10.32+ Amended and Restated Exclusive License Agreement by and between SELLAS Life Sciences Group Ltd and Memorial Sloan Kettering Cancer Center, effective October 11, 2017
−Removed: October 30, 2017
+Added: S-4/A 10.65 October 30, 2017
10.33 Form of Indemnity Agreement between the Registrant and each of its directors and executive officers
−Removed: January 5, 2018
+Added: 8-K 10.8 January 5, 2018
10.34 License Agreement made as of May 19, 2018 by and between the Registrant and 38th Street Suites LLC
−Removed: Surrender Agreement made as of May 19, 2018 by and between the Registrant and Madison Avenue Suites LLC
−Removed: Settlement Agreement between SELLAS Life Sciences Group, Inc.
−Removed: and individual named defendants, on the one hand, and JGB (Cayman) Newton, Ltd., JGB Collateral LLC, JGB Capital Offshore Ltd., JGB Partners L.P., and JGB Capital L.P., on the other hand, dated as of November 5, 2018
−Removed: November 9, 2018
−Removed: Securities Purchase Agreement dated May 10, 2016 between the Registrant and Purchasers
−Removed: Amendment Agreement between the Registrant and JGB (Cayman) Newton Ltd.
−Removed: dated August 22, 2016.
−Removed: August 23, 2016
−Removed: Waiver dated December 14, 2016 to the Securities Purchase Agreement, dated as of May 10, 2016, by and between Registrant and JGB (Cayman) Newton Ltd.
−Removed: February 7, 2017
−Removed: Waiver dated April 1, 2017 to the Securities Purchase Agreement dated as of May 10, 2016 by and between the Registrant and JGB (Cayman) Newton Ltd.
−Removed: April 3, 2017
+Added: 8-K 10.1 May 24, 2018
10.35 Form of Voting Agreement by and between the Registrant and its named executive officers, Board of Directors and certain stockholders
−Removed: March 12, 2018
+Added: 8-K 10.2 March 12, 2018
10.36 Form of Warrant issued pursuant to that certain Securities Purchase Agreement dated March 7, 2018 by and between the Registrant and certain investors
−Removed: March 12, 2018
+Added: 8-K 4.1 March 12, 2018
10.37 Form of Warrant Exercise Agreement dated March 6, 2019
−Removed: March 6, 2019
−Removed: Amendment Agreement dated May 1, 2017 between the Registrant and JGB (Cayman) Newton Ltd.
+Added: 8-K 10.1 March 6, 2019
10.38 Equity Distribution Agreement dated October 29, 2019, between the Registrant and Maxim Group LLC
−Removed: October 31, 2019
+Added: 8-K 10.1 October 31, 2019
10.39 Form of Investor Agreement
+Added: 8-K 10.1 July 9, 2019
10.40 Form of Stock Option Grant Notice and Option Agreement under the 2019 Equity Incentive Plan.
+Added: 10-K 10.48 March 13, 2020
10.41 Form of Restricted Stock Unit Grant and Agreement under the 2019 Equity Incentive Plan.
+Added: 10-K 10.49 March 13, 2020
+Added: 10.42 Amendment to Warrant to Purchase Common Stock dated January 2, 2020 between the Registrant and the holders
+Added: 8-K 10.1 January 7, 2020
+Added: 10.43 Securities Purchase Agreement dated January 9, 2020 between the Registrant and certain Investors
+Added: 8-K 10.1 January 10, 2020
+Added: 10.44 Form of Placement Agent Agreement
+Added: 8-K 1.1 January 10, 2020
+Added: 10.45 Sublease dated June 5, 2020 between the Registrant and Reimer & Braunstein LLP
+Added: 8-K 10.1 June 11, 2020
+Added: 10.46 Securities Purchase Agreement dated July 31, 2020 between the Registrant and certain institutional and accredited investors
+Added: 8-K 10.1 August 4, 2020
+Added: 10.47 Form of Registration Rights Agreement
+Added: 8-K 10.2 August 4, 2020
+Added: 10.48 Exclusive License Agreement dated December 7, 2020 among the Registrant, SLSG Limited, LLC and 3D Medicines Inc.
+Added: 8-K 10.1 January 28, 2021
+Added: 10.49 Share Purchase Agreement dated December 13, 2020 between the Registrant and certain investors
+Added: 8-K 10.1 December 14, 2020
+Added: 10.50 Termination Agreement between the Registrant, The Henry M.
+Added: Jackson Foundation, and the MD Anderson Cancer Center, dated February 4, 2021
14.1 Code of Business Conduct and Ethics
−Removed: January 5, 2018
+Added: 8-K 14.1 January 5, 2018
21.1 Subsidiaries of the Registrant
−Removed: April 13, 2018
23.1 Consent of Moss Adams LLP, Independent Registered Public Accounting Firm
24.1 Powers of Attorney (included on signature page hereto)
+Added: Table of Con tents
+Added: Number Description Form Exhibit Filing Date
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended
2 unchanged sentences
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: XBRL Instance Document.
−Removed: XBRL Taxonomy Extension Schema.
−Removed: XBRL Taxonomy Extension Calculation Linkbase.
−Removed: XBRL Taxonomy Extension Definition Linkbase.
−Removed: XBRL Taxonomy Extension Label Linkbase.
−Removed: XBRL Taxonomy Extension Presentation Linkbase.
+Added: 101.INS*** XBRL Instance Document.
+Added: 101.SCH*** XBRL Taxonomy Extension Schema.
+Added: 101.CAL*** XBRL Taxonomy Extension Calculation Linkbase.
+Added: 101.DEF*** XBRL Taxonomy Extension Definition Linkbase.
+Added: 101.LAB*** XBRL Taxonomy Extension Label Linkbase.
+Added: 101.PRE*** XBRL Taxonomy Extension Presentation Linkbase.
* Indicates management contract or compensatory plans or arrangements.
7 unchanged sentences
FORM 10-K SUMMARY
+Added: Table of Con tents
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
SELLAS Life Sciences Group, Inc.
−Removed: March 13, 2020
+Added: March 23, 2021 By:
/s/ Angelos M.
4 unchanged sentences
In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.
+Added: Signature Title Date
/s/ Angelos M.
−Removed: President, Chief Executive Officer and Director
−Removed: (Principal Executive Officer and Principal Financial Officer)
−Removed: March 13, 2020
+Added: Stergiou President, Chief Executive Officer and Director
+Added: (Principal Executive Officer and Principal Financial Officer) March 23, 2021
Stergiou, M.D., ScD h.c.
−Removed: Vice President, Finance and Corporate Controller
−Removed: (Interim Principal Accounting Officer)
−Removed: March 13, 2020
−Removed: /s/ Jane Wasman
−Removed: Chair of the Board of Directors
−Removed: March 13, 2020
−Removed: /s/ David Scheinberg
−Removed: March 13, 2020
+Added: Burns Vice President, Finance and Corporate Controller, Chief Accounting Officer
+Added: (Principal Accounting Officer) March 23, 2021
+Added: /s/ Jane Wasman Chair of the Board of Directors March 23, 2021
+Added: /s/ David Scheinberg Director March 23, 2021
David Scheinberg, M.D., PhD.
−Removed: /s/ Robert Van Nostrand
−Removed: March 13, 2020
+Added: /s/ Robert Van Nostrand Director March 23, 2021
Robert Van Nostrand
−Removed: /s/ John Varian
−Removed: March 13, 2020
+Added: /s/ John Varian Director March 23, 2021
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.